• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

正常受试者反复服用赖诺普利后的循环血管紧张素II水平。

Circulating angiotensin II levels under repeated administration of lisinopril in normal subjects.

作者信息

Kawamura M, Imanashi M, Matsushima Y, Ito K, Hiramori K

机构信息

Second Department of Internal Medicine, Iwate Medical University, Japan.

出版信息

Clin Exp Pharmacol Physiol. 1992 Aug;19(8):547-53. doi: 10.1111/j.1440-1681.1992.tb00503.x.

DOI:10.1111/j.1440-1681.1992.tb00503.x
PMID:1326422
Abstract
  1. To examine the effect of chronic administration of angiotensin I-converting enzyme (ACE) inhibitor on circulating angiotensin II (AII) concentration, 20 mg of lisinopril was administered once daily for 7 consecutive days to eight healthy volunteers. 2. Plasma ACE activity was inhibited to less than approximately 30% of the pretreatment level during the repeated administration. 3. Mean arterial pressure (MAP) was slightly but significantly reduced during the administration period. Plasma AII concentration measured by an established method using high performance liquid chromatography combined with a radioimmunoassay, however, was maintained at approximately the pretreatment level when it was measured at 24 h intervals after each administration of lisinopril. 4. With the gradual recovery of ACE activity following discontinuation of administration, the plasma AII concentration correlated with AI concentration (r = 0.46), and also with the product of AI and ACE activity (AI x ACE; r = 0.80), corresponding to the formula obtained from the kinetics of ACE activity. No correlation was observed between MAP and AII levels throughout the study period. 5. We conclude that in normal subjects repeatedly administered with ACE inhibitor, the AII level in the circulation is still determined by an elevated level of AI and any remaining ACE activity, thus maintaining AII at pretreatment levels. We confirmed that it is not necessary to achieve a decrease in plasma AII concentration through the chronic administration of ACE inhibitor in order to effectively lower blood pressure.
摘要
  1. 为了研究长期给予血管紧张素I转换酶(ACE)抑制剂对循环中血管紧张素II(AII)浓度的影响,对8名健康志愿者连续7天每天给予20 mg赖诺普利。2. 在重复给药期间,血浆ACE活性被抑制至低于预处理水平的约30%。3. 在给药期间平均动脉压(MAP)略有但显著降低。然而,采用高效液相色谱结合放射免疫分析的既定方法测量的血浆AII浓度,在每次给予赖诺普利后每隔24小时测量时,维持在大约预处理水平。4. 随着给药停止后ACE活性逐渐恢复,血浆AII浓度与AI浓度相关(r = 0.46),也与AI和ACE活性的乘积(AI×ACE;r = 0.80)相关,这与从ACE活性动力学得出的公式一致。在整个研究期间,未观察到MAP与AII水平之间的相关性。5. 我们得出结论,在反复给予ACE抑制剂的正常受试者中,循环中的AII水平仍由升高的AI水平和任何剩余的ACE活性决定,从而将AII维持在预处理水平。我们证实,为有效降低血压,通过长期给予ACE抑制剂来降低血浆AII浓度并非必要。

相似文献

1
Circulating angiotensin II levels under repeated administration of lisinopril in normal subjects.正常受试者反复服用赖诺普利后的循环血管紧张素II水平。
Clin Exp Pharmacol Physiol. 1992 Aug;19(8):547-53. doi: 10.1111/j.1440-1681.1992.tb00503.x.
2
Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure.在慢性心力衰竭患者长期使用赖诺普利治疗期间,血管组织中血管紧张素I向血管紧张素II的转化随时间逐渐重新激活。
J Am Coll Cardiol. 2002 Mar 6;39(5):767-75. doi: 10.1016/s0735-1097(02)01689-3.
3
Gradual reactivation of vascular angiotensin I to angiotensin II conversion during chronic ACE inhibitor therapy in patients with diabetes mellitus.糖尿病患者在慢性血管紧张素转换酶抑制剂治疗期间,血管紧张素I向血管紧张素II的转换逐渐重新激活。
Diabetologia. 2007 Oct;50(10):2061-6. doi: 10.1007/s00125-007-0754-5. Epub 2007 Aug 4.
4
Local generation of angiotensin II as a mechanism of aldosterone secretion in rat adrenal capsules.局部生成血管紧张素II作为大鼠肾上腺被膜中醛固酮分泌的一种机制。
Proc Soc Exp Biol Med. 1991 Feb;196(2):175-7. doi: 10.3181/00379727-196-43175.
5
Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors.肾素-血管紧张素系统阻断对肾脏血管紧张素-(1-7)生成酶及受体的影响。
Kidney Int. 2005 Nov;68(5):2189-96. doi: 10.1111/j.1523-1755.2005.00675.x.
6
Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease.心力衰竭和冠心病患者阻力动脉中血管紧张素转换酶(ACE)及非ACE依赖性血管紧张素II的生成
J Am Coll Cardiol. 2001 Mar 15;37(4):1056-61. doi: 10.1016/s0735-1097(01)01111-1.
7
Acute hemodynamic and hormonal effects of MK-521 in congestive heart failure.MK-521对充血性心力衰竭的急性血流动力学和激素影响。
Scand J Urol Nephrol Suppl. 1984;79:125-7.
8
Release of angiotensin-(1-7) from the rat hindlimb: influence of angiotensin-converting enzyme inhibition.大鼠后肢血管紧张素 -(1 - 7)的释放:血管紧张素转换酶抑制的影响
Hypertension. 2000 Jan;35(1 Pt 2):348-52. doi: 10.1161/01.hyp.35.1.348.
9
Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives.血管紧张素转换酶抑制与血管紧张素II拮抗联合应用对钠缺乏正常血压者血压及肾素释放的相加作用
Circulation. 1995 Aug 15;92(4):825-34. doi: 10.1161/01.cir.92.4.825.
10
Screening of inhibitors of angiotensin-converting enzyme (ACE) employing high performance liquid chromatography-electrospray ionization triple quadrupole mass spectrometry (HPLC-ESI-QqQ-MS).采用高效液相色谱-电喷雾电离三重四极杆质谱法(HPLC-ESI-QqQ-MS)筛选血管紧张素转换酶(ACE)抑制剂。
Eur J Pharm Sci. 2017 Apr 1;101:182-188. doi: 10.1016/j.ejps.2017.02.015. Epub 2017 Feb 9.

引用本文的文献

1
Non-invasive in vivo imaging of changes in Collagen III turnover in myocardial fibrosis.心肌纤维化中Ⅲ型胶原蛋白周转变化的无创体内成像
Npj Imaging. 2024;2(1):33. doi: 10.1038/s44303-024-00037-z. Epub 2024 Sep 17.
2
Beneficial effects of sacubitril/valsartan in heart failure with reduced ejection fraction: pas à cause du BNP?沙库巴曲缬沙坦对射血分数降低的心力衰竭的有益作用:并非因为脑钠肽?
Eur J Heart Fail. 2019 May;21(5):609-612. doi: 10.1002/ejhf.1451. Epub 2019 Mar 4.
3
Valsartan in the treatment of heart attack survivors.缬沙坦用于治疗心脏病发作幸存者。
Vasc Health Risk Manag. 2006;2(2):125-38. doi: 10.2147/vhrm.2006.2.2.125.
4
Is too much neurohormonal blockade harmful?神经激素阻断过度有害吗?
Curr Cardiol Rep. 2004 May;6(3):169-75. doi: 10.1007/s11886-004-0019-6.
5
Enalapril clinical pharmacokinetics and pharmacokinetic-pharmacodynamic relationships. An overview.依那普利的临床药代动力学及药代动力学-药效学关系概述
Clin Pharmacokinet. 1993 Oct;25(4):274-82. doi: 10.2165/00003088-199325040-00003.